Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"When do you expect the business combination to be completed?"
A. It is currently anticipated that the business combination will be consummated promptly following the Redwoods special meeting which is set for [•], 2023, subject to the satisfaction of customary closing conditions; however, such meeting could be adjourned, as described above. For a description of the conditions to the completion of the business combination, please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Business Combination Agreement — Conditions to Closing of the Transactions.”
"Effect of Klotho CRISPR activation and Klotho CRISPR/Cas9 KO plasmids transfection into Caco-2 cells on cell viability and apoptosis."
"The two sgRNAs enhanced Klotho expression at both the gene and protein levels. Our results show the feasibility of gene therapy for targeting Klotho using CRISPR technology."
https://stocktwits.com/StockRoomBully/message/556952019
Pono shareholders approved merger. This is ONLY for reference to Pono closed BCA it was scheduled for February 14, 2024 got closed January 5th see both S-4/A for reference
"The BCA may be terminated by either Pono or Horizon if the Closing has not occurred by February 14, 2024 (unless Pono extends the period of time it has to consummate a business combination)."
So expect news
Pono shareholders approved news January 5th news at 3pm expectations was for February 14, 2024
8k Monday/Tuesday?
4 business days
Redwood acquisition Corp celebrating forgot to release 8k ? 😉
Anew Medical Inc celebrating 🎉👏🎉
As of January 5th no changes/extensions to January 4th 2024 combination closed date per
S-4/A January 3rd 2024 filling
"The Business Combination is expected to close, and the S4 is expected to be effective, in the fourth calendar quarter of 2023, but in no event later than January 4, 2024, following the receipt of the required approval by the stockholders of Redwoods and of ANEW, approval by the Nasdaq Stock Market (“Nasdaq”) of the initial listing application of the combined company filed in connection with the Business Combination, and the fulfillment of other customary closing conditions."
Key notes:
"If Redwoods does not complete a business combination with ANEW or another target business by January 4, 2024"
"The completion window ends on January 4, 2024 (unless otherwise extended in accordance with Redwoods’ charter);"
"On November 27, 2023, Redwoods made a cash contribution of $35,000 to the trust account to extend the business combination period from December 4, 2023 to January 4, 2024. As of [•], 2023, the record date for the special meeting, there was approximately $[•] held in the trust account."
"if Redwoods is unable to complete a business combination prior to January 4, 2024 (unless otherwise extended in accordance with Redwoods’ charter)."
Anticipating Material filling
Per filling BCA March 4th deadline. News any moments . Human clinical trails starts 2024 the BCA runs parallel to the cut of date so any moment now especially no so sign of extended combination date changes/additional $35k for February.
Should expect news of new CFO
There should be another s-4/a for another month if January 4th changes an additional $35k to extend if not 8K
"On November 27, 2023, Redwoods made a cash contribution of $ 35,000 to the Trust Account to extend the business combination period from December 4, 2023 to January 4, 2024."
pay closed attention to both below. The completion combination close date for January 4, 2024 didn't changed even though within the s-4/a fillings votes for December 2023* were reaffirmed which is 3 days already into 2024 on January 3rd 2024
Expecting material events however the BCA termination date is set for March 4th 2024
"On November 4, 2023, Redwoods and ANEW entered into Amendment No.1 to the BCA, pursuant to which the termination date under the BCA was extended to March 4, 2024."
January 3, 2024 - S-4/A: Registration of securities, business combinations - amendment Open document Filing Open filing
December 4, 2023 - S-4/A: Registration of securities, business combinations - amendment Open document Filing Open filing
Seems like a DONE DEAL and waiting on 8k.
"Biosimilar Competition"
"ANEW will face competition in the US, European and other markets from the innovator brand in that market, from biosimilars already approved in those markets, and from biosimilars still in development in those markets. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd. There are two other Avastin biosimilars, Mvasi (bevacizumab-awwb), co-developed by Amgen and Allergan, and Pfizer’s Zirabev (bevacizumab-bvzr).
In Europe, due to immediate acceptance by physicians and government agencies of potential savings due to the price competition of biosimilars, the prices of the innovator’s products came down by 30%-40% or more because of the lower retail prices of the biosimilar product once approved by EMA, whereas in the U.S., biosimilar products approved by FDA are priced at nearly the same price of the innovator’s product. Now, with improving acceptance of biosimilar products in the U.S., prices of both the biosimilar and innovator’s products are coming down, and significant savings are now being realized by the insurance companies and other payors in the U.S."
Agreed! Per fillings
"Avastin® and Rituxan®/Mabthera® are the brand names of bevacizumab and rituximab. Both Genentech in the U.S. and Roche in Switzerland manufacture these antibodies. Rituximab is marketed as Rituxan® in the US and Japan, and branded as Mabthera® outside the US and Japan.
The approved indications for these antibodies are as follows:
Rituxan® (rituximab) is indicated for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL) — Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent, Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy, Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy, Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens. Rituxan is indicated for the treatment of pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL), Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Rituxan is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL) in combination with fludarabine and cyclophosphamide (FC).
135
what is shaping up to be a eye opener. Anew Biosimilar. Most recently FDA approved
FDA Approves Avzivi, the Fifth Biosimilar to Avastin
Dec 19, 2023
"The US Food and Drug Administration (FDA) has approved Avzivi (bevacizumab-tnjn), a biosimilar to Avastin (bevacizumab)."
Note: What is the difference between Avastin and bevacizumab?
Bevacizumab is a type of targeted cancer drug treatment. It is also known as Avastin. It is a treatment for a number of different cancer types.
Note below "Avastin" noticed it said to be similar to "Genentech/Roche"
Anew Medical Inc website
"We are focused on commercializing several blockbuster biologic drugs (antibodies) whose patents have expired and have been proven by our corporate partner to be highly similar to the Genentech/Roche reference antibodies already on the market. These antibody products are referred to as “biosimilars” or “biogenerics”. Our exclusively-licensed portfolio consists biosimilars of Roche/Genentech’s bevacizumab (anti-VEGF, Avastin®) and rituximab (anti-CD20, Mabthera® and Rituxan®).
These two antibody products still provide annual revenue of over $16 Billion to the Roche/Genentech franchise. These are extremely important biologic drugs that are the mainstay or “gold standard” in the treatment of human solid tumors (bevacizumab)."
"a reverse split will no longer be necessary as the combined company will be renamed ANEW MEDICAL Inc. "
F-81
https://www.sec.gov/ix?doc=/Archives/edgar/data/1907223/000121390024000608/fs42023a4_redwoodsacq.htm
And for good reasons.. "I Here we used a CRISPR-dCas9 complex to investigate single-guide RNA (sgRNA) targeting the Klotho promoter region for efficient transcriptional activation of the Klotho gene. We tested the sgRNAs within the - 1 to - 300 bp of the Klotho promoter region and identified two sgRNAs that can effectively enhance Klotho gene transcription. We examined the transcriptional activation of the Klotho gene using three different systems: a Firefly luciferase (FLuc) and NanoLuc luciferase (NLuc) coincidence reporter system, a NLuc knock-in in Klotho 3'-UTR using CRISPR genomic editing"
https://pubmed.ncbi.nlm.nih.gov/29352444/
A voluntary delisting may occur when a company determines that there is no longer a financial benefit to being publicly traded. A buyout: In a buyout, the purchasing entity often takes the purchased company private.
Brock took over everything start to change. Buyout potential/merger. Now they can make. Moves and not be pressured by nasdaq
"I have full faith in Brock's stewardship abilities to lead the company," said Kaspien Board member and Company Co-Founder Tom Simpson. "Brock knows Kaspien and our partners inside and out, and his financial and operational acumen are unmatched. Over the last four years, he has earned and maintained the respect from employees throughout the organization. Brock brings the right combination of vision, pragmatism, and humanity needed to drive a relationship-centric business such as ours."
Now fireweed comes out after 1 year and throw it into the world face and said the real value.
I still hold my shares.. it sad that this goes for penny on the dollar and certain folks kept talking down this potential now we see the real value comes out.
Who bought shares recently at .0001? Shake my head
"The current Mineral Resource at Mactung ranks it the largest high-grade tungsten resource in the world and it is a clear statistical outlier in terms of grade and contained metal*. It is a tungsten skarn deposit associated with Tombstone-Tungsten suite granitic intrusions that are more broadly linked to a variety of gold and tungsten deposits across Yukon-Northwest Territories. The Mactung deposit is sub-divided into an upper and lower zone that both occur at surface and extend to depths of approximately 400 m below surface."
https://finance.yahoo.com/news/fireweed-metals-announces-mineral-resources-151400406.html
The truth about the real value. They gave this away for little to nothing
https://finance.yahoo.com/news/fireweed-metals-announces-mineral-resources-151400406.html
Fireweed Metals Announces Mineral Resources for the Mactung Project: the Largest High-Grade Tungsten Deposit in the World*
"CEO Statement
Brandon Macdonald, CEO, stated “In one year we have gone from signing an initial Letter of Intent to a Definitive Asset Purchase Agreement to the publication of new mineral resource for Mactung. We have taken the historic resource through a process involving relogging, resampling, and a rigorous, modern estimation methodology, and confirmed an impressive and world-class tungsten resource at Mactung*. This not only reaffirms Mactung's unmatched combination of grade and scale but establishes it as a truly strategic critical minerals project for the West with the underground resource alone able to supply much of North America’s expected demand for decades. Fireweed is looking forward to collaborating with federal, territorial, and Indigenous governments to advance Mactung through the permitting and detailed engineering stages of this unique project.”
Checked on this a week ago.. got them shares .. let's see if my account change lol good news
Maybe this have a merger potential down the road. Cantung Mine still up for sale.
Cantung next
Brilliant!
"If you dont know" now ya know"
13m OS 6mill Float MC 2.3mill. Let them chase it. Merger Done
With such a low OS 13mill can you explain to those what this all means? I read somewhere about 30mill per year. What's does this evaluation puts this gem?
Merger official. Folks dont be late
"while the existing STJO shareholders shall retain
the currently issued 13,455,341 shares."
Folks only 13,455,341 shares
Newss
Gerry McIlhargey, President St. Joseph, Inc. (STJO) and Patrick Lewis of RPM Assets, LLC
(RPM), are pleased to jointly announce that the two companies have completed due diligence,
and have come to an agreement to merge RPM, a specialty mainstream and alternative health
and care providing company into STJO (OTC Markets trading symbol STJO) a publicly-traded
company listed on OTC Markets.
As a condition of this agreement, STJO will receive all the assets of RPM for a total of
86,544,659 newly-issued shares of STJO, while the existing STJO shareholders shall retain
the currently issued 13,455,341 shares.
The existing Board of Directors of STJO will tender their resignations, while the management
of RPM will assume the Board of Directors’ positions in STJO. An introductory update of the
new Board members will follow.
RPM would also like to report that
This just heating up. Natuf will be back again 211. Tungsten demand will get this going again
"Stay period deadline April 30th 2022. Td price/change date updated on
April 19th 2022 14:0356 ET
Something cooking..
Its not trading however we posted an image on td that showed an updated mm date thats dated on April 19th 2022 the last update was on December 31st 2021. Now take it for what it is.
Coincidence? End of April deadline is next week
You asked if its trading we shared an update in the trade price/change date. Now in order to get Natuf rolling again a Market Maker get a 211 plus info coming from company.
This is great news seeing price change date updated for 2022 and end of April getting close.
"Northwest Territories & Nunavut: vast, mineral-rich and underexplored"
https://resourceworld.com/northwest-territories-nunavut-vast-mineral-rich-and-underexplored/
Prince Charles visiting Canada for Queen Jubilee why?
Why EUROPEANS making minerals deals with NWT coincidence? Lol
Fact check: Did you know
$Natuf Merge takeover target 211 asap
Filling could get this rolling asap. Nwt news heating up an deals are finally getting done